Photo credit:: PATH Malaria Vaccine inniciative REVOLUTiONiZiNG MALARiA VACCiNATiON
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Photo credit:: PATH Malaria Vaccine inniciative
REVOLUTiONiZiNGMALARiA
VACCiNATiON
Company
Researchspin-off of IMM founded in 2013
Faculdade de Medicina da Universidade de Lisboa,
Centro Hospitalar Lisboa-Norte, 1649 – 028
Lisboa, Portugal
MCRC LisboaNIPC: 513226478
Scientific advisory board
Prof. Dr. Robert W. Saurwein
Prof. Chris J. Janse
Prof. Sangeeta N. Bhatia
Dr. Shahid M. KhanDr. Inigo A-Barturen
Business developmentadvisorsFounders
Validation Phase I funding
100 thousand US$(November 2010)
Phase II funding
1.2 million US$ (November 2013)
Supplement to Phase II funding
320 thousand US$(December 2014)
1st IBERIAN project to receive Phase II funding by BMGF
Business development 1st prize in BES innovation contest (December 2013)
80 thousand US$
Honorable mention in 2013 BGI IUL-MIT competition
Finalist of the 6th Universal Biotech innovation Prize
Finalist of the XII EVERIS Foundation entrepreneur award
Stakeholders
Problem
MALARIA 2.5 billion people at risk of contracting malaria
700 thousand deathsevery year
12 billion US$ in lost GDP of endemic countriesNO EFFECTIVE VACCINE
AVAILABLE
Photo credit: Antonio M. Mendes
Most advanced candidate only affords
~36% protection againsta single parasite species
4.5 billion US$ global
market
Humanitarian market:(estimated value: 3 billion US$)
Private market:(estimated value: 700 million US$)
Tourist & military market:(estimated value: 800 million US$)
Market potential
Photo credit: NYtimes
Do not target the most prevalent parasite, P. vivax
Serious safetyconcerns
Vaccine Approaches
Extremely highdosages
WholeorganismvaccinesShown to confer
>90% sterile protection against a
new infection in Phase I/IIa trialsMandatory high biosafety BSL3
production facilities
Photo credit: worldnaturephoto.com
Plasmodiumberghei
Uniqueness
A SAFE & VERSATILEWHOLE-ORGANISM PLATFORM
FOR VACCINATION AGAINSTMULTIPLE HUMAN
PARASITES
PC
T/IB
2013/053050
Phase I/IIa Clinical trials
Submission of authorization request to regulatory authoritiesEfficacy studies in non-human primate modelPharmacological studies in rabbit model
Expected start date: End of 2015
Strategy
Vaccine Clinical Development(Market entry: 2025)
Production & delivery technology(Market entry: 2016)
Production & delivery
Establishment ofcell culture-based production of sporozoites
Development of a vaccine cryopreservation system
Financial returns
2016 onwards:Cryopreservation technology
100 thousandUS$ / year
2020 - 2015:Vaccination platformLicensing / selling
46 million US$
Related Documents
![Data Sheet Universal Force / Torque Gauge Model BGI · 2020. 7. 21. · Model BGI. BGI Specifications. Dimensions. in [mm] Ordering Information. The BGI and all sensors are supplied](https://static.cupdf.com/doc/110x72/60c0a6b66b69f75b48415e42/data-sheet-universal-force-torque-gauge-model-bgi-2020-7-21-model-bgi-bgi.jpg)
